The WFH Gene Therapy Registry (GTR) is a prospective, observational, and longitudinal registry designed to collect long-term data on people with hemophilia (PWH) who receive gene therapy. The primary objective of the GTR is to determine the long-term safety of factor VIII and factor IX gene therapies for PWH. Secondary objectives are to determine the long-term efficacy and the durability of factor VIII and factor IX gene therapies in PWH, and to assess long-term quality of life and burden of disease post gene-therapy infusion. The added data from ATHN—a nonprofit organization dedicated to improving the lives of people affected by bleeding and clotting disorders—will, along with other national registries worldwide, further enrich the data in the GTR, making it an even more valuable resource.
The creation of a global registry is critical to ensure the data needed to assess the long-term risks, safety, and effectiveness of gene therapy in hemophilia is available to the bleeding disorders community. The WFH and ATHN will work collaboratively towards this end as part of this important project.
To find out more about the WFH Gene Therapy Registry (GTR), click here. To find out more about the American Thrombosis and Hemostasis Network (ATHN), contact [email protected].
The WFH Gene Therapy Registry is supported by WFH Founding visionary partners BioMarin Pharmaceutical Inc., CSL Behring, Pfizer, and Spark Therapeutics.